De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
MacroGenics Beheer
Beheer criteriumcontroles 3/4
De CEO MacroGenics' is Scott Koenig, benoemd in Sep2001, heeft een ambtstermijn van 23.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.71M, bestaande uit 19% salaris en 81% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.07% van de aandelen van het bedrijf, ter waarde $ 4.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.7 jaar en 7.3 jaar.
Belangrijke informatie
Scott Koenig
Algemeen directeur
US$3.7m
Totale compensatie
| Percentage CEO-salaris | 19.0% |
| Dienstverband CEO | 23.1yrs |
| Eigendom CEO | 2.1% |
| Management gemiddelde ambtstermijn | 7.7yrs |
| Gemiddelde ambtstermijn bestuur | 7.3yrs |
Recente managementupdates
Recent updates
Party Time: Brokers Just Made Major Increases To Their MacroGenics, Inc. (NASDAQ:MGNX) Earnings Forecasts
Aug 01
MacroGenics, Inc.'s (NASDAQ:MGNX) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Jul 30We're A Little Worried About MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Jul 12MacroGenics, Inc.'s (NASDAQ:MGNX) 81% Dip In Price Shows Sentiment Is Matching Revenues
May 13MacroGenics: Strong Likelihood Bad News Has Caused Overreaction (Rating Upgrade)
May 13MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024
Apr 05MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 28MacroGenics: Trying To Build A Better Everything
Feb 15There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues
Jan 09Benign Growth For MacroGenics, Inc. (NASDAQ:MGNX) Underpins Its Share Price
May 17Analyst Forecasts For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Mar 11Here's Why MacroGenics (NASDAQ:MGNX) Must Use Its Cash Wisely
Jan 25Analysts' Revenue Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Are Surging Higher
Oct 25MacroGenics: No Near-Term Catalysts
Oct 11Israel Englander and his Millennium fund disclose 5.2% passive stake in MacroGenics
Sep 02MacroGenics Q2 2022 Earnings Preview
Aug 05Companies Like MacroGenics (NASDAQ:MGNX) Could Be Quite Risky
Jul 25MacroGenics halts mid-stage head and neck cancer study after fatalities
Jul 11The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
May 09We're Keeping An Eye On MacroGenics' (NASDAQ:MGNX) Cash Burn Rate
Apr 12MacroGenics: Facing Considerable Headwinds From Unsatisfactory Trials
Feb 25Estimating The Intrinsic Value Of MacroGenics, Inc. (NASDAQ:MGNX)
Feb 18Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$136m |
| Mar 31 2024 | n/a | n/a | -US$23m |
| Dec 31 2023 | US$4m | US$705k | -US$9m |
| Sep 30 2023 | n/a | n/a | US$50m |
| Jun 30 2023 | n/a | n/a | US$7m |
| Mar 31 2023 | n/a | n/a | -US$91m |
| Dec 31 2022 | US$5m | US$673k | -US$120m |
| Sep 30 2022 | n/a | n/a | -US$191m |
| Jun 30 2022 | n/a | n/a | -US$219m |
| Mar 31 2022 | n/a | n/a | -US$217m |
| Dec 31 2021 | US$5m | US$651k | -US$202m |
| Sep 30 2021 | n/a | n/a | -US$146m |
| Jun 30 2021 | n/a | n/a | -US$129m |
| Mar 31 2021 | n/a | n/a | -US$136m |
| Dec 31 2020 | US$3m | US$656k | -US$130m |
| Sep 30 2020 | n/a | n/a | -US$158m |
| Jun 30 2020 | n/a | n/a | -US$167m |
| Mar 31 2020 | n/a | n/a | -US$152m |
| Dec 31 2019 | US$5m | US$590k | -US$152m |
| Sep 30 2019 | n/a | n/a | -US$166m |
| Jun 30 2019 | n/a | n/a | -US$155m |
| Mar 31 2019 | n/a | n/a | -US$167m |
| Dec 31 2018 | US$5m | US$599k | -US$171m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$34m |
| Mar 31 2018 | n/a | n/a | -US$32m |
| Dec 31 2017 | US$3m | US$554k | -US$20m |
Compensatie versus markt: De totale vergoeding ($USD 3.71M ) Scott } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).
Compensatie versus inkomsten: De vergoeding van Scott is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Scott Koenig (72 yo)
23.1yrs
Tenure
US$3,705,825
Compensatie
Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 23.1yrs | US$3.71m | 2.07% $ 4.5m | |
| Senior VP | 16.4yrs | US$1.58m | 0.27% $ 588.1k | |
| Senior VP of Clinical Development & Chief Medical Officer | 4.3yrs | US$1.75m | 0.016% $ 33.6k | |
| Chief Operating Officer | 2.7yrs | US$1.92m | 0.062% $ 133.4k | |
| Senior Vice President of Technical Operations | 1.9yrs | US$1.88m | 0.013% $ 28.5k | |
| Senior VP of Research & Chief Scientific Officer | 8.1yrs | US$2.29m | 0.16% $ 346.1k | |
| Senior VP | 7.3yrs | geen gegevens | 0% $ 0 | |
| VP, Controller & Treasurer | 21yrs | geen gegevens | 0.0099% $ 21.3k |
7.7yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van MGNX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.7 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 23.1yrs | US$3.71m | 2.07% $ 4.5m | |
| Independent Director | 11.1yrs | US$160.75k | 0.0072% $ 15.4k | |
| Independent Director | 3.7yrs | US$152.00k | 0.0072% $ 15.4k | |
| Independent Director | 20yrs | US$147.63k | 0.060% $ 128.9k | |
| Independent Director | 1.8yrs | US$318.32k | 0.0072% $ 15.4k | |
| Independent Chairman of the Board | 2.4yrs | US$180.13k | 0.0072% $ 15.4k | |
| Independent Director | 1.8yrs | US$335.41k | 0.0072% $ 15.4k | |
| Independent Director | 7.8yrs | US$167.63k | 0.0072% $ 15.4k | |
| Independent Director | 6.9yrs | US$167.21k | 0.0072% $ 15.4k | |
| Independent Director | 7.8yrs | US$135.75k | 0.0072% $ 15.4k |
7.3yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van MGNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.3 jaar).